Provided by Tiger Trade Technology Pte. Ltd.

Aurinia Pharmaceuticals

14.21
-0.3500-2.40%
Post-market: 14.210.00000.00%17:50 EDT
Volume:1.61M
Turnover:22.66M
Market Cap:1.89B
PE:6.86
High:14.56
Open:14.50
Low:13.85
Close:14.56
52wk High:16.54
52wk Low:6.83
Shares:132.97M
Float Shares:128.06M
Volume Ratio:1.25
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.07
EPS(LYR):2.07
ROE:59.91%
ROA:11.16%
PB:3.25
PE(LYR):6.86

Loading ...

Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c

TIPRANKS
·
Feb 26

Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $1.53

MT Newswires Live
·
Feb 26

Aurinia Pharmaceuticals Q4 EPS $1.53, Sales $77.114M Beat $74.845M Estimate

Benzinga
·
Feb 26

BRIEF-Aurinia Pharmaceuticals Q4 Product Revenue USD 74.173 Million

Reuters
·
Feb 26

Aurinia Pharmaceuticals Q4 Operating Income USD 33.239 Million

THOMSON REUTERS
·
Feb 26

Aurinia Pharmaceuticals Inc: Plan to Initiate a Clinical Study in an Additional Autoimmune Disease in H1 2026

THOMSON REUTERS
·
Feb 26

Aurinia Pharmaceuticals Q4 Operating Expenses USD 43.875 Million

THOMSON REUTERS
·
Feb 26

Aurinia Pharmaceuticals Inc: Outlook 2026 Total Revenue of $315 Mln to $325 Mln

THOMSON REUTERS
·
Feb 26

Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Dow Jones
·
Feb 26

Aurinia Pharmaceuticals Inc expected to post earnings of 22 cents a share - Earnings Preview

Reuters
·
Feb 24

BRIEF-Aurinia Pharmaceuticals To Report Financial Results For The Three And Twelve Months Ended December 31, 2025

Reuters
·
Feb 19

Aurinia Pharmaceuticals Inc. Updates Financial Calendar

Reuters
·
Feb 19

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

THOMSON REUTERS
·
Feb 19

Saturn Oil & Gas Completes Amalgamation with Subsidiaries

Reuters
·
Jan 02

STEP Energy Services Ltd. Held Shareholder Meeting

Reuters
·
Dec 13, 2025

Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade

MT Newswires Live
·
Dec 04, 2025

Aurinia Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
Dec 03, 2025

Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15

MT Newswires Live
·
Dec 03, 2025

Aurinia Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $16 From $15

THOMSON REUTERS
·
Dec 03, 2025

A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Share Price Gains

Simply Wall St.
·
Nov 28, 2025